source
- Trump administration’s MFN drug pricing deals may cut projected Medicare savings by up to 80%The White House announced "most-favored-nation" pricing agreements with 26 pharmaceutical companies, saying the contracts would lower drug costs for federal programs. The deals require companies to…
- Roche presents positive Phase 2 results for enicepatide in overweight and obese type 2 diabetes patientsRoche has released new data from a Phase 2 trial of enicepatide, a peptide acquired from Carmot Therapeutics, focusing on overweight or obese adults with type 2 diabetes. The trial met its primary…